Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AcSDKP-NH2 + inulin is a combination of two agents: - **AcSDKP-NH2 (N-acetyl-seryl-aspartyl-lysyl-proline amide)** is a synthetic or modified form of the endogenous tetrapeptide AcSDKP, which has demonstrated anti-inflammatory and antifibrotic properties. It acts by regulating inflammation, inhibiting fibrosis, and modulating tissue repair processes. AcSDKP is naturally released from thymosin β4 via enzymatic cleavage involving meprin-α and prolyl oligopeptidase. Its therapeutic potential has been explored for conditions such as diabetic nephropathy and other fibroproliferative diseases[1][2]. - **Inulin** is a naturally occurring polysaccharide classified as a dietary fiber. It serves primarily as a prebiotic agent to promote gut health but also exhibits hypolipidemic, hypoglycemic, antitumor, antimicrobial effects and may improve mineral absorption[6]. The rationale for combining these agents would likely be to leverage the anti-fibrotic/anti-inflammatory actions of AcSDKP with the gut-modulating or metabolic benefits of inulin; however, there are no established pharmaceutical products or clinical trials specifically investigating this exact combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AcSDKP-NH2 + inulin.